2016•Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)Open access

Protein kinase C (PKC) delta activation negatively regulates phorbol 12-myristate 13-acetate (PMA) induced superoxide (SO) release in polymorphonuclear leukocytes (PMNs)

Stephanie Liu, Stephanie Percy, Samuel Johannson, Christine Adekayode, Gregory Stoner, Amelie Bottex, Jovan S. Adams, Robert Barsotti, Qian Chen

Open full text 0 citations

Abstract

It’s known that PMA is a broad-spectrum PKC activator that augments SO release in PMNs viaNADPH oxidase activation. It was shown that PKC delta (δ) negatively regulates PMN elastase release which suggests that PKC δ may also negatively regulate PMN NADPH oxidase SO release. To test the hypothesis, we altered PKC δ activity using selective cell permeable PKC δ activator, inhibitor peptides, and rottlerin, another type of PKC δ inhibitor. We predict that PKC δ activation would attenuate PMA-induced PMN SO release, whereas PKC δ inhibition would augment the response. Isolated PMNs (5x106) from male Sprague-Dawley rats were incubated in the presence/absence of PKC δ activator (Myr-MRAAEDPM, MW=1130 g/mol, 2.5-20 µM, n=6-8), PKC δ inhibitor (Myr-SFNSYELGSL, MW=1326 g/mol, 1-20 µM, n=6-10) or rottlerin (MW=516 g/mol, 2.5-20 µM, n=8-9) prior to PMA (MW=616 g/mol, 15 or 30 nM, n=11-16) stimulation. SO release was measured spectrophotometrically by the reduction of ferricytochrome C. At the end of the assay, cell viability was determined by 0.3% trypan blue exclusion. As expected, PKC δ peptide activator attenuated PMN SO release up to 56%, whereas, rottlerin augmented the PMA response up to 90% compared to untreated controls (p92±5% in all study groups. The data suggest that PKC δ negatively regulates PMN NADPH oxidase SO release. PKC δ peptide inhibitor is relatively ineffective regulating PMN SO release compared to rottlerin.

Open-access reader

About this research paper

What this paper is about

It’s known that PMA is a broad-spectrum PKC activator that augments SO release in PMNs viaNADPH oxidase activation. It was shown that PKC delta (δ) negatively regulates PMN elastase release which suggests that PKC δ may also negatively regulate PMN NADPH oxidase SO release. To test the hypothesis, we altered PKC δ activity using selective cell permeable PKC δ activator, inhibitor peptides, and rottlerin, another type of PKC δ inhibitor. We predict that PKC δ activation would attenuate PMA-induced PMN SO release, whereas PKC δ inhibition would augment the response. Isolated PMNs (5x106) from male Sprague-Dawley rats were incubated in the presence/absence of PKC δ activator (Myr-MRAAEDPM, MW=1130 g/mol, 2.5-20 µM, n=6-8), PKC δ inhibitor (Myr-SFNSYELGSL, MW=1326 g/mol, 1-20 µM, n=6-10) or rottlerin (MW=516 g/mol, 2.5-20 µM, n=8-9) prior to PMA (MW=616 g/mol, 15 or 30 nM, n=11-16) stimulation. SO release was measured spectrophotometrically by the reduction of ferricytochrome C. At the end of the assay, cell viability was determined by 0.3% trypan blue exclusion. As expected, PKC δ peptide activator attenuated PMN SO release up to 56%, whereas, rottlerin augmented the PMA response up to 90% compared to untreated controls (p92±5% in all study groups. The data suggest that PKC δ negatively regulates PMN NADPH oxidase SO release. PKC δ peptide inhibitor is relatively ineffective regulating PMN SO release compared to rottlerin.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

It’s known that PMA is a broad-spectrum PKC activator that augments SO release in PMNs viaNADPH oxidase activation. It was shown that PKC delta (δ) negatively regulates PMN elastase release which suggests that PKC δ may also negatively regulate PMN NADPH oxidase SO release. To test the hypothesis, we altered PKC δ activity using selective cell permeable PKC δ activator, inhibitor peptides, and rottlerin, another type of PKC δ inhibitor. We predict that PKC δ activation would attenuate PMA-induced PMN SO release, whereas PKC δ inhibition would augment the response. Isolated PMNs (5x106) from male Sprague-Dawley rats were incubated in the presence/absence of PKC δ activator (Myr-MRAAEDPM, MW=1130 g/mol, 2.5-20 µM, n=6-8), PKC δ inhibitor (Myr-SFNSYELGSL, MW=1326 g/mol, 1-20 µM, n=6-10) or rottlerin (MW=516 g/mol, 2.5-20 µM, n=8-9) prior to PMA (MW=616 g/mol, 15 or 30 nM, n=11-16) stimulation. SO release was measured spectrophotometrically by the reduction of ferricytochrome C. At the end of the assay, cell viability was determined by 0.3% trypan blue exclusion. As expected, PKC δ peptide activator attenuated PMN SO release up to 56%, whereas, rottlerin augmented the PMA response up to 90% compared to untreated controls (p92±5% in all study groups. The data suggest that PKC δ negatively regulates PMN NADPH oxidase SO release. PKC δ peptide inhibitor is relatively ineffective regulating PMN SO release compared to rottlerin.

Key concepts: Rottlerin, Protein kinase C, Phorbol, NADPH oxidase, Superoxide, Superoxide dismutase, Chemistry, Molecular biology

Related papers

Back to paper searchBrowse research topicsOriginal source
Protein kinase C (PKC) delta activation negatively regulates phorbol 12-myristate 13-acetate (PMA) induced superoxide (SO) release in polymorphonuclear leukocytes (PMNs) — Research Paper | ScholarLens